GLP-1 Evidence

Lijek

Semaglutid: šta pokazuju ispitivanja

Semaglutid u dozi od 2,4 mg nedeljno proizveo je oko 15% prosečnog gubitka telesne težine tokom 68 nedelja. Ta brojka je stvarna, replikovana i često pogrešno tumačena.

Ažurirano 3 min čitanja 32 citati Snaga dokaza 5/5

Labave okrugle tablete sa otisnutim identifikacionim kodom, viđene odozgo
Larry D. Moore · CC BY 4.0 · Wikimedia Commons

Glavno ispitivanje

STEP 1 je randomizovao odrasle sa prekomernom težinom ili gojaznošću i bez dijabetesa na nedeljni semaglutid 2,4 mg ili placebo, oba uz intervenciju u načinu života, tokom 68 nedelja [9]. Prosečna promena težine bila je oko −14,9% na lijeku u poređenju sa −2,4% na placebu. Otprilike trećina učesnika na lijeku izgubila je 20% ili više telesne težine — ishod koji je ranije bio domen bariatricne hirurgije.

Dve stvari su vredne zadržavanja. Prvo, to je prosečna: raspodela je široka, a značajna manjina gubi vrlo malo. Drugo, placebo grupa je takođe primila savetovanje o načinu života, tako da 2,4% nije "ne raditi ništa" — efekat lijeka se meri pored saveta koji sam po sebi čini nešto.

Broj je manji ako imate dijabetes

STEP 2 je sproveo isti dizajn kod odraslih sa dijabetesom tipa 2 i pronašao otprilike 9,6% gubitka težine u istoj dozi [8]. Ta razlika između otprilike 15% i otprilike 10% ponavlja se kroz klasu i nije specifična za semaglutid. Uporedna meta-analiza među GLP-1 agonistima pokazuje isti obrazac na težini i glikemijskim krajnjim tačkama [3].

Semaglutid 2,4 mg nedeljno — prosečna promena težine po populaciji
IspitivanjePopulacijaTrajanjeProsječna promjena težinePlacebo
STEP 1 [9]Pretilost, bez dijabetesa68 nedelja≈ −14,9%≈ −2,4%
STEP 2 [8]Pretilost + dijabetes tipa 268 nedelja≈ −9,6%≈ −3,4%
STEP 4 [7]Nastavljeno vs prekinuto nakon 20 nedelja48 dodatnih nedeljaNastavljeno: dalji gubitakPrekinuto: povratak
SELECT [5]Gojaznost + kardiovaskularna oboljenja~4 godineOdržano ≈ −10%≈ −1,5%

Koliko dugo to nastavlja da deluje?

Duže nego što su sugerisala ispitivanja od 68 nedelja. Meta-analiza dugoročnih podataka pokazala je da se efekat održava dobro izvan jedne godine [1], a SELECT kardiovaskularno ispitivanje — koje je trajalo oko četiri godine i nije bilo dizajnirano kao ispitivanje težine — pokazalo je da se gubitak težine stabilizuje na otprilike 10% i zatim se održava, a ne smanjuje [5]. Stabilizacija je stvarna; povratak koji su kritičari predviđali nije, pod uslovom da se tretman nastavi.

Održani gubitak težine uz nastavak tretmana

Semaglutid naspram tirzepatida

Za dijabetes tipa 2, SURPASS-2 je uporedio tirzepatid sa semaglutidom 1 mg i favorizovao tirzepatid. Za gojaznost posebno, direktno poređenje na dozama za gojaznost došlo je kasnije i bilo je odlučujuće: tirzepatid je proizveo znatno veći prosečan gubitak težine od semaglutida [10], u skladu sa ranijim stvarnim i indirektnim poređenjima [11].

To automatski ne čini tirzepatid pravim izborom za pojedinca — podnošljivost, troškovi, dostupnost i komorbiditeti svi utiču na to — ali samo na osnovu gubitka težine redosled nije sporan. Pogledajte tirzepatid.

Gdje semaglutid ima smjernicu iza sebe

Osim gubitka težine, semaglutid je prešao u formalne smjernice za metaboličku disfunkciju povezanu sa steatoznom bolešću jetre, gdje zajedničke evropske smjernice obrađuju njegovu ulogu [2]. Takođe je jedini agens u klasi sa završenim ispitivanjem kardiovaskularnih ishoda u ne-dijabetičkoj gojaznoj populaciji [5], što je obuhvaćeno na kardiovaskularnoj stranici.

Hemijski laboratorijski radni sto sa staklenom opremom i bocama reagensa na mestu
Cjp24 · CC BY-SA 3.0 · Wikimedia Commons

Česta pitanja

Da li je Wegovy drugačiji od Ozempica?
Ista molekula, različita licencirana doza i indikacija. Ispitivanja za gojaznost koristila su 2,4 mg nedeljno; doziranje za dijabetes je niže. Efekti navedeni za gubitak težine dolaze iz više doze.
Zašto sam izgubio manje od 15%?
Zato što je 15% prosek. Odgovor se široko razlikuje među pojedincima u svakom ispitivanju, a ljudi sa dijabetesom tipa 2 gube otprilike trećinu manje u proseku [8].
Da li prestaje da deluje nakon nekoliko meseci?
Ne. Gubitak težine usporava i stabilizuje se, obično tokom druge godine, ali dugoročni podaci pokazuju da se gubitak održava uz nastavak tretmana [1][5].
Mogu li ga uzeti samo da izgubim nekoliko kilograma i onda prestati?
Možete, ali očekujte da će se većina gubitka vratiti. To je dosljedan nalaz podataka o povlačenju [6][7] i o tome se detaljno raspravlja na stranici o prestanku.
Dokazi iza ove stranice Stog grafikon koji prikazuje sastav 12 publikacija citiranih na ovoj stranici prema vrsti studije. 4101meta-analysis (4)randomised trial (10)other (1)
11 publikacija, 2021–2025. To je mješavina koja uključuje i ispitivanja i sinteze, što je pozicija iz koje je tvrdnja o uzroku razumna. Izvor: vlastita lista citata ove stranice, ispod.

Reference

Svaka citacija u nastavku povezuje na izvorni recenzirani zapis na PubMed-u ili putem DOI-a. Ništa ovdje nije zamjena za medicinski savjet.

  1. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism: clinical and experimental · 2025 · Meta-analysis DOIPubMed 39719170
  2. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  3. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Moiz A, Levett JY, Filion KB, et al. · The American journal of cardiology · 2024 · Meta-analysis DOIPubMed 38679221
  4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Journal of hepatology · 2024 · Clinical guideline DOIPubMed 38851997
  5. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024 · Systematic review DOIPubMed 38629387
  6. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Yao H, Zhang A, Li D, et al. · BMJ (Clinical research ed.) · 2024 · Meta-analysis DOIPubMed 38286487Full text
  7. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review Feier CVI, Vonica RC, Faur AM, et al. · International journal of molecular sciences · 2024 · Systematic review DOIPubMed 38673931Full text
  8. Once-weekly  semaglutide  for obesity  or overweight: A systematic review and meta-analysis He K, Guo Q, Zhang H, et al. · Diabetes, obesity & metabolism · 2022 · Meta-analysis DOIPubMed 34866313
  9. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Tan HC, Dampil OA, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022 · Meta-analysis DOIPubMed 36578889Full text
  10. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial Wharton S, Freitas P, Hjelmesæth J, et al. · The lancet. Diabetes & endocrinology · 2025 · Randomised controlled trial DOIPubMed 40961952
  11. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity Wharton S, Lingvay I, Bogdanski P, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40934115
  12. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity Garvey WT, Blüher M, Osorto Contreras CK, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544433
  13. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes Davies MJ, Bajaj HS, Broholm C, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544432
  14. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease Cummings JL, Atri A, Feldman HH, et al. · Alzheimer's research & therapy · 2025 · Randomised controlled trial DOIPubMed 39780249Full text
  15. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Butler J, Shah SJ, Petrie MC, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 38599221Full text
  16. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  17. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38740993Full text
  18. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial Colhoun HM, Lingvay I, Brown PM, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38796653Full text
  19. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Bliddal H, Bays H, Czernichow S, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOIPubMed 39476339
  20. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37952131
  21. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Kadowaki T, Isendahl J, Khalid U, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35131037
  22. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Garvey WT, Batterham RL, Bhatta M, et al. · Nature medicine · 2022 · Randomised controlled trial DOIPubMed 36216945Full text
  23. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Wilding JPH, Batterham RL, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 35441470Full text
  24. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial Wadden TA, Bailey TS, Billings LK, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33625476Full text
  25. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Rubino D, Abrahamsson N, Davies M, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33755728Full text
  26. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Davies M, Færch L, Jeppesen OK, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 33667417
  27. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 33567185
  28. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Friedrichsen M, Breitschaft A, Tadayon S, et al. · Diabetes, obesity & metabolism · 2021 · Randomised controlled trial DOIPubMed 33269530Full text
  29. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial Pratley RE, Aroda VR, Lingvay I, et al. · The lancet. Diabetes & endocrinology · 2018 · Randomised controlled trial DOIPubMed 29397376
  30. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Blundell J, Finlayson G, Axelsen M, et al. · Diabetes, obesity & metabolism · 2017 · Randomised controlled trial DOIPubMed 28266779Full text
  31. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Aronne LJ, Horn DB, le Roux CW, et al. · The New England journal of medicine · 2025 · Clinical trial DOIPubMed 40353578
  32. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. · JAMA internal medicine · 2024 · Journal article DOIPubMed 38976257Full text

Ova stranica je automatski prevedena sa engleskog. Citati i brojevi su nepromijenjeni. Pročitajte engleski original ako nešto zvuči čudno. Pročitajte engleski original